SG11201704244SA - 2-aminopyrimidine compound and pharmaceutical composition and use thereof - Google Patents
2-aminopyrimidine compound and pharmaceutical composition and use thereofInfo
- Publication number
- SG11201704244SA SG11201704244SA SG11201704244SA SG11201704244SA SG11201704244SA SG 11201704244S A SG11201704244S A SG 11201704244SA SG 11201704244S A SG11201704244S A SG 11201704244SA SG 11201704244S A SG11201704244S A SG 11201704244SA SG 11201704244S A SG11201704244S A SG 11201704244SA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- aminopyrimidine compound
- aminopyrimidine
- compound
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410682756.9A CN105601573B (zh) | 2014-11-24 | 2014-11-24 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
| PCT/CN2015/094954 WO2016082713A1 (zh) | 2014-11-24 | 2015-11-18 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704244SA true SG11201704244SA (en) | 2017-06-29 |
Family
ID=55982000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704244SA SG11201704244SA (en) | 2014-11-24 | 2015-11-18 | 2-aminopyrimidine compound and pharmaceutical composition and use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10059694B2 (de) |
| EP (1) | EP3225619B1 (de) |
| JP (1) | JP6474068B2 (de) |
| KR (1) | KR101941929B1 (de) |
| CN (2) | CN105601573B (de) |
| AU (1) | AU2015353210B2 (de) |
| CA (1) | CA2968633C (de) |
| IL (1) | IL252477B (de) |
| NZ (1) | NZ733009A (de) |
| RU (1) | RU2704129C2 (de) |
| SG (1) | SG11201704244SA (de) |
| WO (1) | WO2016082713A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105601573B (zh) * | 2014-11-24 | 2021-07-02 | 中国科学院上海药物研究所 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
| CN106928150B (zh) * | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| CN107417626B (zh) * | 2016-05-23 | 2020-01-24 | 江苏奥赛康药业有限公司 | 一种2-氨基嘧啶类化合物的多晶型形式 |
| CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
| CN108498477A (zh) * | 2017-02-27 | 2018-09-07 | 江苏奥赛康药业股份有限公司 | 一种2-氨基嘧啶类化合物的药用组合物及其制备方法 |
| PL3656769T3 (pl) * | 2017-07-19 | 2023-03-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Związek arylo-fosforowo-tlenowy jako inhibitor kinazy egfr |
| KR20190108079A (ko) * | 2018-03-13 | 2019-09-23 | 보로노이바이오 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN110305161A (zh) * | 2018-03-20 | 2019-10-08 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| WO2019196838A1 (zh) * | 2018-04-13 | 2019-10-17 | 江苏奥赛康药业有限公司 | 一种2-氨基嘧啶类化合物的药学上可接受的盐 |
| WO2020038434A1 (zh) * | 2018-08-23 | 2020-02-27 | 江苏奥赛康药业有限公司 | 一种2-氨基嘧啶类化合物的药用组合物 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| TW202128670A (zh) * | 2019-11-26 | 2021-08-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮多環類衍生物抑制劑、其製備方法和應用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113304325B (zh) * | 2020-02-27 | 2022-03-11 | 四川大学 | 一种集可注射与抗菌于一体的双功能水凝胶及其制备方法和用途 |
| CN113493420A (zh) * | 2020-03-18 | 2021-10-12 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| WO2021244502A1 (zh) * | 2020-06-03 | 2021-12-09 | 江苏先声药业有限公司 | 多芳基化合物及应用 |
| CN115536699B (zh) * | 2022-12-01 | 2023-05-23 | 北京鑫开元医药科技有限公司 | 一种新型EGFR-TKIs、制备方法、药物组合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| US20090149467A1 (en) * | 2005-09-15 | 2009-06-11 | Merck & Co., Inc. | Tyrosine Kinase Inhibitors |
| PL2154967T3 (pl) | 2007-04-16 | 2014-08-29 | Hutchison Medipharma Entpr Ltd | Pochodne pirymidyny |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| SG10201510696RA (en) * | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| JP6068451B2 (ja) * | 2011-05-17 | 2017-01-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | キナーゼ阻害剤 |
| AU2013204563B2 (en) * | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| CN105601573B (zh) * | 2014-11-24 | 2021-07-02 | 中国科学院上海药物研究所 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
-
2014
- 2014-11-24 CN CN201410682756.9A patent/CN105601573B/zh active Active
-
2015
- 2015-11-18 WO PCT/CN2015/094954 patent/WO2016082713A1/zh active Application Filing
- 2015-11-18 JP JP2017528838A patent/JP6474068B2/ja active Active
- 2015-11-18 CA CA2968633A patent/CA2968633C/en active Active
- 2015-11-18 US US15/529,333 patent/US10059694B2/en active Active
- 2015-11-18 EP EP15863532.6A patent/EP3225619B1/de active Active
- 2015-11-18 CN CN201580016514.9A patent/CN106458930B/zh active Active
- 2015-11-18 RU RU2017122062A patent/RU2704129C2/ru active
- 2015-11-18 NZ NZ733009A patent/NZ733009A/en unknown
- 2015-11-18 KR KR1020177017442A patent/KR101941929B1/ko active IP Right Grant
- 2015-11-18 SG SG11201704244SA patent/SG11201704244SA/en unknown
- 2015-11-18 AU AU2015353210A patent/AU2015353210B2/en active Active
-
2017
- 2017-05-24 IL IL252477A patent/IL252477B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170131341A (ko) | 2017-11-29 |
| IL252477A0 (en) | 2017-07-31 |
| CN106458930A (zh) | 2017-02-22 |
| EP3225619A4 (de) | 2018-05-23 |
| RU2017122062A3 (de) | 2018-12-26 |
| JP6474068B2 (ja) | 2019-02-27 |
| US10059694B2 (en) | 2018-08-28 |
| WO2016082713A1 (zh) | 2016-06-02 |
| EP3225619B1 (de) | 2020-10-14 |
| JP2017535589A (ja) | 2017-11-30 |
| CN106458930B (zh) | 2019-10-11 |
| CN105601573A (zh) | 2016-05-25 |
| CA2968633A1 (en) | 2016-06-02 |
| RU2704129C2 (ru) | 2019-10-24 |
| AU2015353210A1 (en) | 2017-07-13 |
| CA2968633C (en) | 2020-06-30 |
| KR101941929B1 (ko) | 2019-01-24 |
| RU2017122062A (ru) | 2018-12-26 |
| US20170283398A1 (en) | 2017-10-05 |
| NZ733009A (en) | 2018-10-26 |
| IL252477B (en) | 2021-04-29 |
| EP3225619A1 (de) | 2017-10-04 |
| CN105601573B (zh) | 2021-07-02 |
| AU2015353210B2 (en) | 2019-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252477A0 (en) | 2-aminopyrimidine compound, pharmaceutical structure and its use | |
| HK1249103B (zh) | 多環氨甲醯基吡啶酮化合物及其藥物用途 | |
| HK1244000B (zh) | 多環氨基甲酰吡啶酮化合物及其藥物用途 | |
| HK1232137A1 (zh) | 治療化合物和組合物 | |
| GB201409471D0 (en) | Pharmaceutical composition | |
| GB201409488D0 (en) | Pharmaceutical composition | |
| HK1245086A1 (zh) | 處方藥物組成及其製備和使用 | |
| GB201409485D0 (en) | Pharmaceutical composition | |
| ZA201703398B (en) | Pharmaceutical composition and methods | |
| HK1245085A1 (zh) | 處方藥物組成及其製備和使用 | |
| PT3202759T (pt) | Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| HK1245113A1 (zh) | 藥物組合物及其用途 | |
| ZA201502073B (en) | Pharmaceutical composition | |
| ZA201508726B (en) | Pharmaceutical composition | |
| SG11201608123VA (en) | Pharmaceutical composition for external use | |
| LT3089740T (lt) | Farmacinė kompozicija | |
| SG11201608124XA (en) | Pharmaceutical composition for external use | |
| SG10201504332VA (en) | Pharmaceutical Composition | |
| SG11201608122PA (en) | Pharmaceutical composition for external use |